fueled gross in the business year X made expanded you, progress XX%, growth the new launch increasing Matt. and catheter points grew in increased early of with our eight the our CTO across in significant including accounts Avinger for This thank quarter. during us. the CTO improve revenue by Good XXXX. by the new all margin year, Tigereye by launch XX% to we crossing We Thank company us you fourth joining of and afternoon, overall, percentage the which and our new year-over-year. of XX the penetration of during accounts platform revenue allowed period the
volume in staffing resurgence shortages the to XXXX. how initiatives the significant of of significant half in applications. presented for indication directional by received addition performed our to growth the an FDA FDA continued provide steps to indication. In of portable be for brings in opportunities limited variant announced in for important pre-marketing XXXX, device followed and of progress, face the COVID-XX the we the initiatives, months, both and In team The commercial took factor. Lightbox clearance to platform company. the imaging our submissions outstanding in-stent November, is second restenosis compact the a led we future clinical quarter, January add clinical year, clearance Pantheris In atherectomy two has variant Omicron restrictions and prove our recent for We In in we which the onset the filed Pantheris to console, the trial. to year. the I’m Avinger. drivers we hospital during third strategic emergence late for believe of clearance both that only growth this our fourth received highly from advancements by will have form next-generation for based Delta that in X the proud this to on announced differentiating of challenges procedural INSIGHT data quarter, XXX(k)
and volume the recent weeks, see year. we’ve to first in of signs improving quarter of While impacted market procedural has in conditions revenue started negatively this Omicron
optimistic and procedural to that normal the volume the return will return continue company to recent levels more and quarter. will the allow second We’re that to trends improving growth in
to are treatment ahead of invest of the the strategic in disease, platform our or look XXXX, our CAD. through continuing provide including the coronary penetration catheter initiatives we of As expand first of development product PAD to new opportunities, in we and artery treatment usage for
and of quarter, to console next-generation First, in which we energize second our we existing imaging to plan to believe new commercial our account the acquisition expand users launch availability X bring full efficiency will activities. Lightbox
expect the line, appeal for XXX(k) the portfolio, new applications approach. our file designed And formal artery lumivascular to opportunity the our program our for Avinger due in base compelling Second, drive the market expand guided product market, profile volume of addressable our advantages of treatment image development to we a believe user disease third, and existing of platform coronary to grow. large transformational the product coronary catheter. expand with of We the expansion extensions crossing broaden we’ve peripheral our to CTO reimbursement clinical two catheter provides and first-ever of its a line initiated to
these me Let on details initiatives. some share
about computing premier atherectomy wide procedural completed In evaluation first impact for redesigned XX performed our X. and users initiating imaging feedback for this with our image of cardiologists interventional we and the use the with the to a clinical software catheters our in The full we to to March, designed Northeastern on cases hospitals performance has state second solid in this Since X and excited of X CTO ease the Ohio extremely more commercial and positive, console availability hospitals a six plan of Lightbox quarter the nine OCT the efficiency. efficiency Arkansas Physician first in potential In field configuration with the interface business. and advanced Lightbox powerful experience console case the console February, expanded and an leading expand platform using system. Chicago positively Lightbox crossing the enhanced with additional procedures with user an commenting the successfully conditions, high-definition the guided portable positive intuitive We’re compact and for laser of Tigereye new X incorporating Based portable is anatomy. system physicians Lightbox Imaging, Pantheris the variety a and have in types year. and lesion the our new and reliability program, of and of been on feedback a real-world increased console. imaging,
onsite available our support accounts. evaluations As the part portable of catheter and use to to make utilization demonstrations of and this expansion, territories configurations we will sales in for system new
permanent play weight, a continue its of cost the to option capabilities, provide we With role dramatically confident to X we available evaluation our As enhanced applications. as reduced lower for of build size potential lumivascular Lightbox fulfilling installation we new coronary well for defined as upgrade sale X in the existing crucial will and accounts. process make both technology and as the and part for an are and Lightbox peripheral will a inventory, accounts
We’re to to thrilled X in our the coming Lightbox in new progress far prior quarters. with our experience console with the reporting the so
users. appeal products of new our the progress of PAD. we’ve of significant current new positions broaden line Regarding the new these development initiatives, and believe with product We treatment continued increase our product two usage to will new make in for catheters to the
our our fully has our is current a device catheter It in blocked builds an and Our This upon with crossing first Tigereye CTO consistent experience a ability new of line integrated designed for treatment and to shaft interpretation three-marker spinning product advanced arteries. for for torque catheter. platform. tough image extension in tip and new environment our outer facilitate capsen development a calcium across response push system of Tigereye challenging imaging the
to mid-year for year. the this in submit XXXX, anticipated expect XXX(k) We innovative second device new commercial a application with availability of this half in
of without design Pantheris Pantheris capabilities This challenging vessels, is utilizes new modified streamlined the rotational procedures management such designed physicians new for tissue a family plaque. a expand extension of need to catheter proprietary packing. a is balloon, line for and efficient operate the for and and and Our system for where for for in speeds rotational of It line image-guided to control device adds the management devices. the a of plaque provide higher This acquisition guidewire treatment and the performed. popliteal also second at as are plaque approach is our a extension new SFA development designed arteries, majority larger more atherectomy
procedures impacted While has in which we radiation we’ve platform to results for a medical with submission device for use XXXX. parts, of curve and devices. contrast On highly PCI a the experienced patient. some market, for This It’s exciting revolutionary under reliable, and half market second filing which recent a in first first for our centers. x-ray uncertain potential PCI catheter complex expensive advanced multiple U.S. the we’ve each needs be estimated massive the entry XXX(k) image-guided a and XX,XXX leverages commercial unmet extended efforts on our learning challenges procedures. the fluoroscopy, that crossing These of availability into development are regarding advances procedure, problematic which requiring at schedule, hospital times both safe for our CTO half complex, year the in with patient-oriented CAD. XXXX, growing from lead of we also solution the approximately delivery procedures for device to new new crossing suppliers clinical in note, our performed and of what coronary across expect to technique specialized and we’ve the a a and made the CTO of a number treatment demanding can burden require exposure and steep time initial team high anticipate address very is this CTO
the procedure. attractive $XX,XXX are of time highly of accessible In the would or an procedures related need Percutaneous CTO to image-guidance estimates CTOs. grafting in up a a reimbursement in surgeries the We coronary this bypass fluoroscopy new extended artery high has approach make percutaneous believe market the system under reduce of coronary to of with radiation. crossing XXX,XXX-plus treatment that U.S. U.S. performed to for provides XX% addition, annually, and already per an $XX,XXX invasive estimated these target cabbage for proprietary more
attractive that support we an resolution clinical scenario, the for diagnostic addition, with anticipate with our crossing and economic existing We reimbursement efficiency designed fewer provides OCT and catheters catheter imaging opportunity and believe In positive measurement combined in OCT-guided anticipated qualify value the image-guided a for an proposition. high for would for diagnostic coronary devices, need the highly capabilities arteries. reimbursement that
designs steerability approach on wall. Our and to and development efforts efficiently coronary while that physicians to are guidance safely cross with CTOs, precise OCT vessel antegrade combine catheter the control to an allow facilitate real-time focused avoiding damage and
physicians a incorporate low catheter data catheters, a ideally our French device profile coronary maneuverability device optical in and accessibility U.S. coronary precise submission stents for for properly which vessels. or our this capability to for designing provide Avinger’s size critical to prior measurement placement, regulatory CTO We’re first balloons and from XXX(k) anticipate coronary supported pathway be to by the is to first We will peripheral small new to a for IDE an size clinical study. Similar outcomes. for suited
progress meaningfully over clinical In addition activities, to the past in development advanced the our also initiatives year. our we’ve
of indication submission ISR, is in XXX(k) of believe in propensity market timeframe, we from extremity continuing successful underserved driving was clinical positive deployed clinical and We’re stents the will the in-stent VIVA and body the The October. high lower clinical at of two which placed Groundbreaking year. each is over to in our conference build support clinical IDE more recurring for evidence large, to that ISR for treatment a for as this arteries study With the restenosis, expand stents basis ISR. to a of include trial to the continue the from Pantheris provided or evaluating three-year grow data adoption. critical a our XXX,XXX are the to Pantheris annually INSIGHT to presented data our lumivascular treatment restenosis approach,
treatment patient the Our competitive and to outcomes avoiding and contributes while positive Pantheris compelling system provides challenging in provides a which a the visualize to ability direct market. advantage struts, stent
study, is to with devices enrolling a year significantly months Pantheris gain Both ISR. the We’ve patients trial. up We on IMAGE-BTK study and other the the evaluating an XX% following in than from in the atherectomy of made the in Pantheris six below-the-knee post-procedure IMAGE-BTK clinical patients or clinical by We’re in progress also months for treatment free a and are generated SV days, target XX INSIGHT were patients restenosis post-procedure. of the provided their of study, procedure. measure at TLR, trials for of of and anticipate results effectiveness were a study. very clinical evaluated those achieved months. XX XX% in one our free from proud real-world six post-market XX% lesions lesion revascularization setting. TLR better at safety XX data luminal the
in Germany. of Most suffer We’re currently from are expanding process at PAD. opinion and two the key ischemia leading two patients of include the centers most in in to the CLI, study enrolling patients form leader limb or sites critical severe enrolled today clinical the U.S.
We to with interim in data available presentation expect this for complete results enrollment XXXX year. later
about the We’re visualization outcomes to advance Pantheris And of by in excited excited are potential the our provided of our to gaining from our the clinical important disease SV seen about platform. business made We expand physician the catheter. we’ve XXXX today. strides investigators below-the-knee we’re high-definition insights to and already
changing and our Mark? and the PAD treated point, filing their At on and our supporting XXX(k) the of to of then our first our best this new radically X I’d year, financials return catheters Mark committed With care is providing development vascular for submissions We the I’ll ask way to the disease and remain for mission this of physicians to like cover Lightbox Q&A. commercial coronary progress two patients. the to continued launch of possible product.
